Related Experiment Video
Updated: Mar 24, 2026

14:19
Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
Published on: June 29, 2013
28.8K
Intrauterine growth restriction - part 2
Deepak Sharma1, Nazanin Farahbakhsh2, Sweta Shastri3
1a Department of Pediatrics , Pt B.D. Sharma, Post Graduate Institute of Medical and Sciences , Rohtak , Haryana , India .
Summary
Small for gestational age (SGA) infants and intrauterine growth restriction (IUGR) face significant health challenges. This review covers their classification, diagnosis, and complications, highlighting increased neonatal mortality and morbidity.
Area of Science:
- Neonatology
- Pediatric Growth and Development
Background:
- Small for gestational age (SGA) and intrauterine growth restriction (IUGR) are associated with increased perinatal and neonatal mortality.
- SGA infants experience higher rates of complications like asphyxia, hypothermia, and hypoglycemia compared to appropriate for gestational age infants.
- These infants also face growth retardation and neurodevelopmental handicaps.
Purpose of the Study:
- To review the classification and diagnosis of neonatal IUGR.
- To discuss the short-term and long-term complications in infants with IUGR.
- To provide an overview of the challenges faced by SGA/IUGR infants.
Main Methods:
- Literature review on SGA and IUGR definitions and outcomes.
- Analysis of neonatal classification and diagnostic criteria for IUGR.
- Synthesis of data on perinatal morbidity and mortality associated with SGA/IUGR.
Main Results:
- SGA/IUGR infants exhibit higher rates of adverse neonatal outcomes.
- Despite technological advancements, perinatal morbidity and mortality remain elevated.
- The review details various complications and neurodevelopmental issues.
Conclusions:
- Neonatal IUGR classification and diagnosis are crucial for management.
- Understanding short-term and long-term complications is vital for improving infant outcomes.
- Continued research and improved clinical practices are needed to reduce SGA/IUGR-related morbidity and mortality.
Related Concept Videos
Intrauterine Drug Delivery Systems
123
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
123
Teratogenicity
4.5K
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.5K

